7-Amino-2-phenylpyrazolo[4,3-d]pyrimidine derivatives: Structural investigations at the 5-position to target human A1 and A 2A adenosine receptors. Molecular modeling and pharmacological studies

European Journal of Medicinal Chemistry

Volumn 84, Issue , 2014, Pages 614-627

  Squarcialupi, Lucia ^a   Colotta, Vittoria ^a   Catarzi, Daniela ^a   Varano, Flavia ^a   Betti, Marco ^a   Varani, Katia ^b   Vincenzi, Fabrizio ^b   Borea, Pier Andrea ^b   Porta, Nicola ^c   Ciancetta, Antonella ^c   Moro, Stefano ^c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

G protein coupled receptors; Ligand adenosine receptor modeling studies; Pyrazolo 4,3 d pyrimidines

Indexed keywords

2 PHENYL 5 (2 PHENYLETHENYL) 2H PYRAZOLO[4,3 D]PYRIMIDIN 7 AMINE; 2 PHENYL 5 (3 PHENYLPROPYL) 2H PYRAZOLO[4,3 D]PYRIMIDIN 7 AMINE; 2 PHENYL 5 (3 TRIFLUOROMETHYLBENZYL) 2H PYRAZOLO[4,3 D]PYRIMIDIN 7 AMINE; 5 (2 CHLOROBENZYL) 2 PHENYL 2H PYRAZOLO[4,3 D]PYRIMIDIN 7 AMINE; 5 (2 FLUOROBENZYL) 2 PHENYL 2H PYRAZOLO[4,3 D]PYRIMIDIN 7 AMINE; 5 (2 HYDROXYBENZYL) 2 PHENYL 2H PYRAZOLO[4,3 D]PYRIMIDIN 7 AMINE; 5 (2 METHOXYBENZYL) 2 PHENYL 2H PYRAZOLO[4,3 D]PYRIMIDIN 7 AMINE; 5 (3 CHLOROBENZYL) 2 PHENYL 2H PYRAZOLO[4,3 D]PYRIMIDIN 7 AMINE; 5 (3 HYDROXYBENZYL) 2 PHENYL 2H PYRAZOLO[4,3 D]PYRIMIDIN 7 AMINE; 5 (3 METHOXYBENZYL) 2 PHENYL 2H PYRAZOLO[4,3 D]PYRIMIDIN 7 AMINE; 5 (3 METHYLBENZYL) 2 PHENYL 2H PYRAZOLO[4,3 D]PYRIMIDIN 7 AMINE; 5 (3,4 METHYLENEDIOXYBENZYL) 2 PHENYL 2H PYRAZOLO[4,3 D]PYRIMIDIN 7 AMINE; 5 (4 CHLOROBENZYL) 2 PHENYL 2H PYRAZOLO[4,3 D]PYRIMIDIN 7 AMINE; 5 (4 HYDROXYBENZYL) 2 PHENYL 2H PYRAZOLO[4,3 D]PYRIMIDIN 7 AMINE; 5 (4 HYDROXYPHENETHYL) 2 PHENYL 2H PYRAZOLO[4,3 D]PYRIMIDIN 7 AMINE; 5 (4 METHOXYBENZYL) 2 PHENYL 2H PYRAZOLO[4,3 D]PYRIMIDIN 7 AMINE; 5 (4 METHOXYPHENETHYL) 2 PHENYL 2H PYRAZOLO[4,3 D]PYRIMIDIN 7 AMINE; 5 (4 METHYLBENZYL) 2 PHENYL 2H PYRAZOLO[4,3 D]PYRIMIDIN 7 AMINE; 5 ISOBUTYL 2 PHENYL 2H PYRAZOLO[4,3 D]PYRIMIDIN 7 AMINE; 5 ISOPROPYL 2 PHENYL 2H PYRAZOLO[4,3 D]PYRIMIDIN 7 AMINE; 5 PHENETHYL 2 PHENYL 2H PYRAZOLO[4,3 D]PYRIMIDIN 7 AMINE; 5 [2 (4 HYDROXYPHENYL)ETHENYL] 2 PHENYL 2H PYRAZOLO[4,3 D]PYRIMIDIN 7 AMINE; 5 [2 (4 METHOXYPHENYL)ETHENYL] 2 PHENYL 2H PYRAZOLO[4,3 D]PYRIMIDIN 7 AMINE; 5 [3 (2 METHOXYPHENYL)PROPYL] 2 PHENYL 2H PYRAZOLO[4,3 D]PYRIMIDIN 7 AMINE; 5 [3 (3 METHOXYPHENYL)PROPYL] 2 PHENYL 2H PYRAZOLO[4,3 D]PYRIMIDIN 7 AMINE; 5 [3 (4 METHOXYPHENYL)PROPYL] 2 PHENYL 2H PYRAZOLO[4,3 D]PYRIMIDIN 7 AMINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; PYRAZOLOPYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; 2 PHENYL 2H PYRAZOLO[4,3 D]PYRIMIDIN 7 AMINE; 2 PHENYL 5 (3 TRIFLUOROMETHYLBENZYL) 2H PYRAZOLO[4,3 D] PYRIMIDIN 7 AMINE; 2 PHENYL 5 [2 PHENYLETHENYL] 2H PYRAZOLO[4,3 D]PYRIMIDIN 7 AMINE; 5 ETHYL 2 PHENYL 2H PYRAZOLO[4,3 D]PYRIMIDIN 7 AMINE; 5 [2 (4 HYDROXYPHENYL)ETHENYL] 2 PHENYL 2H PYRAZOLO; 5 [2 (4 METHOXYPHENYL)ETHENYL] 2 PHENYL 2H PYRAZOLO; 7 AMINO 2 PHENYLPYRAZOLO[4,3 D]PYRIMIDINE DERIVATIVE; ADENOSINE A2 RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; PYRIMIDINE DERIVATIVE; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2 RECEPTOR ANTAGONIST; PYRAZOLE DERIVATIVE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CHO CELL LINE; COMPUTER MODEL; DRUG BINDING; DRUG POTENCY; DRUG SYNTHESIS; FEMALE; MOLECULAR MODEL; NONHUMAN; STRUCTURE ACTIVITY RELATION; CAMP ASSAY; DRUG BINDING SITE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; IC50; ISOMERIZATION; LIGAND BINDING; MICROWAVE IRRADIATION; STATIC ELECTRICITY; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; HUMAN; METABOLISM; SYNTHESIS;

ADENOSINE A1 RECEPTOR ANTAGONISTS; ADENOSINE A2 RECEPTOR ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PYRAZOLES; PYRIMIDINES; RECEPTOR, ADENOSINE A1; RECEPTOR, ADENOSINE A2A; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84905052014     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.07.060     Document Type: Article

References (65)

1. B.B. Fredholm, A.P. IJzerman, K.A. Jacobson, K.-N. Klotz, and J. Linden International union of pharmacology XXV. Nomenclature and classification of adenosine receptors Pharmacol. Rev. 53 2001 527 552 (Pubitemid 33136237)
2. B.B. Fredholm, A.P. IJzerman, K.A. Jacobson, J. Linden, and C.E. Muller International union of pharmacology LXXXI. Nomenclature and classification of adenosine receptors. An up date Pharmacol. Rev. 63 2011 1 34
3. K.A. Jacobson, and L.J.S. Knutsen P1 and P2 purine and pyrimidine receptor ligands M.P. Abbracchio, M. Williams, Purinergic and Pyrimidinergic Signalling Handbook of Experimental Pharmacology vol. 151/1 2001 129 175 Berlin
4. 1 receptor antagonists in clinical research and development Kidney Int. 78 2010 438 445
5. K.A. Jacobson, and Z.-G. Gao Adenosine receptors as therapeutic targets Nat. Rev. Drug Discov. 5 2006 247 264 (Pubitemid 43336037)
6. M.T. Slawsky, and M.M. Givertz Rolofylline: a selective adenosine 1 receptor antagonist for the treatment of heart failure Expert Opin. Pharmacother. 10 2009 311 322
7. 1 receptors J. Pharmacol. Sci. 96 2004 42 52 (Pubitemid 39318777)
8. 2A receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: comparison with existing anti-Parkinson's disease drugs Behav. Brain Res. 194 2008 152 161
9. 2A receptors control neuroinflammation and consequent hippocampal neuronal dysfunction J. Neurochem. 117 2011 100 111
10. 2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation Prog. Neurobiol. 83 2007 310 331 (Pubitemid 350119825)
11. 2A receptors in Parkinson's disease Trends Neurosci. 29 2006 647 654 (Pubitemid 44602262)
12. (2A) adenosine receptor antagonists in the therapy of Parkinson's disease Pharmacol. Ther. 132 2011 280 299
13. J.-F. Chen, H.K. Eltzschig, and B.B. Fredholm Adenosine receptors as drug targets - what are the challenges? Nat. Rev. Drug Discov. 12 2013 265 286
14. Kyowa Hakko Kirin Approval for Manufacturing and Marketing of NOURIAST Tablets 20 mg. A Novel Antiparkinsonian Agent 2013 http: www.kyowakirin.com/ news.releases/2013/e20130325-04.htlm
15. 2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex Psychopharmacology 230 2013 345 352
16. 2A receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease Brain Res. 1367 2011 310 318
17. 2A receptor antagonists: recent developments Curr. Med. Chem. 13 2006 3609 3625 (Pubitemid 44873735)
18. V. Colotta, D. Catarzi, F. Varano, L. Cecchi, G. Filacchioni, C. Martini, L. Trincavelli, and A. Lucacchini 1,2,4-Triazolo[4,3-A]quinoxalin-1-one: a versatile tool for the synthesis of potent and selective adenosine receptor antagonists J. Med. Chem. 43 2000 1158 1164 (Pubitemid 30173741)
19. V. Colotta, D. Catarzi, F. Varano, L. Cecchi, G. Filacchioni, C. Martini, L. Trincavelli, and A. Lucacchini Synthesis and structure-activity relationships of a new set of 2-arylpyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists J. Med. Chem. 43 2000 3118 3124 (Pubitemid 30627970)
20. 3 adenosine receptor antagonists: synthesis, pharmacological and ligand-receptor modeling studies J. Med. Chem. 47 2004 3580 3590 (Pubitemid 38822019)
21. 3 adenosine receptor antagonists Bioorg. Med. Chem. 13 2005 705 715 (Pubitemid 40093613)
22. 3 adenosine receptor antagonists: synthesis, biological evaluation and molecular modeling studies of 2-(hetero)aryl- and 2-carboxy-substituted derivatives J. Med. Chem. 48 2005 7932 7945 (Pubitemid 41799618)
23. 3 adenosine receptor antagonists. Synthesis, pharmacological evaluation and ligand-receptor modeling studies J. Med. Chem. 49 2006 3916 3925 (Pubitemid 43967888)
24. 3 adenosine receptor antagonists. Synthesis, pharmacological evaluation and ligand-receptor modeling studies J. Med. Chem. 50 2007 4061 4074 (Pubitemid 47301738)
25. 3 adenosine receptor antagonist binding mode using a molecular simplification approach: from triazoloquinoxaline to a pyrimidine skeleton as a key study J. Med. Chem. 50 2007 6596 6606
26. 3 adenosine receptor antagonists Bioorg. Med. Chem. 16 2008 6086 6102 (Pubitemid 351766717)
27. 3 adenosine receptor antagonists belonging to the 4-amido-2-arylpyrazolo[3,4-c]quinoline series. Molecular docking analysis and pharmacological studies Bioorg. Med. Chem. 17 2009 401 410
28. 3 adenosine receptor antagonists. Synthesis, pharmacological evaluation and ligand-receptor modeling studies J. Med. Chem. 52 2009 2407 2419
29. 3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition J. Med. Chem. 52 2009 7640 7652
30. 3 adenosine receptor antagonists J. Med. Chem. 54 2011 2102 2113
31. 3 adenosine receptor antagonists. Molecular modeling studies and pharmacological evaluation J. Med. Chem. 56 2013 2256 2269
32. S.M. Mc Elvain, and J.W. Nelson the preparation of orthoesters J. Am. Chem. Soc. 64 1942 1825 1827
33. E. Chorell, J.S. Pinkner, C. Bengtsson, T. Sainte-Luce Banchelin, S. Edvinsson, A. Linusson, S.J. Hultgren, and F. Almqvist Mapping pilicide anti-virulence effect in Escherichia coli, a comprehensive structure-activity study Bioorg. Med. Chem. 20 2012 3128 3142
34. R.F. Clark, N.Y. Ba-Maung, S.A. Erickson, S.D. Fidanze, R.A. Mantei, G.S. Sheppard, B.K. Sorensen, G.T. Wang, J. Wang, R.L. Bell, Preparation of pyrimidine inhibitors of kinase activity, WO2010/138575 A1, 2010.
35. 1B/1D serotonin receptor ligands: a structure-affinity investigation J. Med. Chem. 41 1998 2243 2251 (Pubitemid 28285726)
36. K. Krohn, C. Franke, P.G. Jones, H.-J. Aust, S. Draeger, and B. Schulz Isolierung, synthese und biologische wirkung von coniothyriomycin sowie synthese un biotestung analoger offenkettinger imide Liebigs Ann. Chem. 1992 789 798
37. B. Kahveci Synthesis of 4-amino-4,5-dihydro-1H-1,2,4-triazole-5-ones and their isatin-3-imine derivatives Molecules 10 2005 376 382 (Pubitemid 40632779)
38. G. Grella, G. Paglietti, F. Sparatore, M. Satta, P. Manca, and A. Peana Synthesis and choleretic activity of 3-[2-(3-R′,4-R″,5-R″- benzyl-benzyl)-5-R-benzimidazol-1-yl]butanoic acids Farmaco 47 1992 21 35 (Pubitemid 23178261)
39. F. Almqvist, E. Chorell, P. Das, H. Emtenaes, O. Fjellstroem, M. Mogemark, M. Polla, V. Veronica, 1H-Pyridin-2-one derivatives as PAI-1 inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases, PCT Int. Appl., WO2008054290, A1 20080508, 2008.
40. O. Bekircan, and H. Bektas Synthesis of Schiff and Mannich bases of isatin derivatives with 4-amino-4,5-dihydro-1H-1,2,4-triazole-5-ones Molecules 13 2008 2126 2135
41. J. Zemlicka, and M. Murata Some transformations of DL-phenylalanine ortho esters and N-benzyloxycarbonyl-L-phenylalaninal J. Org. Chem. 41 1976 3317 3321
42. N.R. Curtis, H.J. Diggle, J.J. Kulagowski, C. London, S. Grimwood, P.H. Hutson, F. Murray, P. Richards, A. Macaulayc, and K.A. Wafford Novel N1-(Benzyl)cinnamamidine derived NR2B subtype-selective NMDA receptor antagonists Bioorg. Med. Chem. Lett. 13 2003 693 696 (Pubitemid 36298470)
43. C. Davrinche, J.-D. Brion, and P. Reynaud Aldolic condensation on inorganic solid support: application to the synthesis of O-ethyl esters of 3-phenyl-2-propenethioic acids Synth. Comm. 14 1894 1181 1190
44. 15N] labelled DL-homophenylalanine via a key Neber rearrangement J. Label. Compd. Rad. 41 1998 29 36 (Pubitemid 28046578)
45. 1A receptor agonists endowed with antinociceptive activity in vivo J. Med. Chem. 56 2013 7851 7861
46. J.J. Venit, M. Di Pierro, and P. Magnus Studies on the synthesis of l-azaspiro[5.5]undecanes related to histrionicotoxin J. Org. Chem. 54 1989 4298 4301
47. N. Kurono, T. Inoue, and M. Tokuda Facile preparation of organozinc bromides using electrogenerated highly reactive zinc and its use in cross-coupling reaction Tetrahedron 61 2005 11125 11131 (Pubitemid 41502890)
48. 3 adenosine receptor: a review of novel patented ligands Expert Opin. Ther. Pat. 22 2012 369 390
49. W. Liu, E. Chun, A.A. Thompson, P. Chubukov, F. Xu, V. Katritch, G. Won Han, C.B. Roth, L.H. Heitman, A.P. IJzerman, V. Cherezov, and R.C. Stevens Structural basis for allosteric regulation of GPCRs by sodium ions Science 337 2012 232 236
50. 2A adenosine receptor J. Biol. Chem. 270 1995 13987 13997
51. 3 adenosine receptor J. Biol. Chem. 277 2002 19056 19063 (Pubitemid 34952470)
52. V. Katritch, I. Kufareva, and R. Abagyan Structure-based prediction of subtype-selectivity for adenosine receptor antagonists Neuropharmacology 60 2011 108 115
53. Molecular Operating Environment (MOE), 2012.10, Chemical Computing Group Inc., 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2012.
54. J.J.P. Stewart MOPAC 7 1993 Fujitsu Limited Tokyo, Japan
55. GOLD Suite, Version 5.1, Cambridge Crystallographic Data Centre, Cambridge, U.K. http://www.ccdc.cam.ac.uk.
56. M. Floris, D. Sabbadin, R. Medda, A. Bulfone, and S. Moro Adenosiland: walking through adenosine receptors landscape Eur. J. Med. Chem. 58 2012 248 257
57. J.A. Ballesteros, and H. Weinstein Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors Methods Neurosci. 25 1995 366 428
58. 2A receptor as a case study J. Chem. Inf. Model. 2014 10.10121/ci5002857
59. 2A adenosine receptors Life Sci. 59 1996 1373 1388 (Pubitemid 26344372)
60. 2A receptor signalling in striatal cells expressing mutant huntigtin FASEB J. 15 2001 1245 1247
61. 3 adenosine receptors Life Sci. 63 1998 81 87 (Pubitemid 28335639)
62. 2B receptors Biochem. Pharmacol. 70 2005 1601 1612 (Pubitemid 41540353)
63. M.M. Bradford A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein dye-binding Anal. Biochem. 72 1976 248 254
64. 50) of an enzymatic reaction Biochem. Pharmacol. 22 1973 3099 3108
65. P.J. Munson, and D. Rodbard Ligand: a versatile computerized approach for the characterization of ligand binding systems Anal. Biochem. 107 1980 220 239